Abstract
When data fail to support fully mechanistic models, alternative modeling strategies must be pursued. Simpler, more empirical models or the fixing of various rate constants are necessary to avoid over-parameterization. Fitting empirical models can dilute information, limit interpretation, and cloud inference. Fixing rate constants requires external, relevant, and reliable information on the mechanism and can introduce subjectivity as well as complicate determining the validity of model extrapolation. Furthermore, both these methods ignore the possibility that failure of the data to support the mechanistic model could contain information about the pharmacodynamic process. If the pathway has processes with “fast” dynamics, these steps could collapse yielding parametrically simpler classes of models. The collapsed models would retain the mechanistic interpretation of the full model, which is crucial for performing substantive inference, while reducing the number of parameters to be estimated. These concepts are illustrated through their manifestations on the dose–effect relationship and ensuing dose selection for a proof of concept study. Specifically, a mechanistic model for a selective irreversible antagonist was posited and candidate classes of models were derived utilizing “fast dynamics” assumptions. Model assessment determined the rate-limiting step facilitating pertinent inference with respect to the mechanism. For comparison, inference using a more empirical modeling strategy is also presented. A general solution for the collapse of the typical PK–PD model differential equations is provided in Appendix A
Similar content being viewed by others
References
N.L. Dayneka V. Garg W.J. Jusko (1993) ArticleTitleComparison of four basic models of indirect pharmacodynamic responses J. Pharmacokin. Biopharm 21 457–478 Occurrence Handle10.1007/BF01061691 Occurrence Handle1:CAS:528:DyaK2cXitlGhsb0%3D
P.O. Gisleskog M.O. Karlsson S.L. Beal (2003) ArticleTitleUse of prior information to stabilize a population data analysis J. Pharmacokin. Pharmacodyn 29 473–505
D. Verotta L.B. Sheiner (1995) ArticleTitleA general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data J. Pharmacokin. Biopharm 23 1–4 Occurrence Handle1:STN:280:BymC2MbotVM%3D
W.J. Jusko H.C. Ko W.F. Ebling (1995) ArticleTitleConvergence of direct and indirect pharmacodynamic response models J. Pharmacokin. Biopharm 23 5–8 Occurrence Handle1:STN:280:BymC2MbotVw%3D
K. Higaki S. Yamashita G.L. Amidon (2001) ArticleTitleTime dependent oral absorption models J. Pharmacokin. Pharmacodyn 28 109–128 Occurrence Handle1:STN:280:DC%2BD38%2FhtV2hsw%3D%3D Occurrence Handle10.1023/A:1011573831444
Beal S.L., Sheiner L.B., (eds). NONMEM Users Guides, NONMEM Project Group, University of California, San Francisco, CA, 1996.
Y. Yano S.L. Beal L.B. Sheiner (2001) ArticleTitleEvaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J. Pharmacokin. Pharmacodyn 28 171–192 Occurrence Handle1:STN:280:DC%2BD38%2FhtV2htg%3D%3D
P.O. Gisleskog D. Hermann M. Hammarlund-Udenaes M.O. Karlsson (1998) ArticleTitleA model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductace inhibitors GI198745 and finasteride Clin. Pharm. Therapeut 64 636–647 Occurrence Handle1:STN:280:DyaK1M%2FovVGqtg%3D%3D
A. Sharma W.J. Jusko (1996) ArticleTitleCharacterization of four basic model of indirect pharmacodynamic responses J. Pharmacokin. Biopharm 24 611–635 Occurrence Handle1:STN:280:ByiH2crks1w%3D
G.J. Hahn (1970) ArticleTitleStatistical intervals for a normal population part Tables I., examples, and applications J. Qual. Tech 2 115–126
B. Efron (1982) The Jackknife, The Bootstrap and Other Resampling Plans Society for Industrial and Applied mathematics Bristol, England
D. Verotta L.B. Sheiner (1995) ArticleTitleRejoinder J. Pharmacokin. Biopharm 23 9–10
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hutmacher, M.M., Mukherjee, D., Kowalski, K.G. et al. Collapsing Mechanistic Models: An Application to Dose Selection for Proof of Concept of a Selective Irreversible Antagonist. J Pharmacokinet Pharmacodyn 32, 501–520 (2005). https://doi.org/10.1007/s10928-005-0052-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10928-005-0052-0